Antinuclear antibodies and response to IFNβ-Ia therapy in relapsing-remitting multiple sclerosis

O. Ciccarelli, F. Bagnato, C. Mainero, M. Salvetti, A. Paolillo, C. Gasperini, S. Bastianello, C. Pozzilli

Research output: Contribution to journalArticlepeer-review


We determined whether positive ANA was related to response to rIFNβ-Ia in 62 relapsing-remitting MS patients. According to the presence of antinuclear antibodies (ANA) at baseline and during the first 6 months of treatment, patients were sorted in different groups. The clinical and MRI outcome during short-term (6 months) and long-term (24 months) treatment period was not statistically different between the groups. Therefore, the response to IFNβ-Ia seems not to be influenced by ANA occurrence either before or during treatment. When the analysis was extended to other autoantibodies (i.e. antithyroid, anticardiolipin) similar results were obtained.

Original languageEnglish
Pages (from-to)137-139
Number of pages3
JournalMultiple Sclerosis Journal
Issue number3
Publication statusPublished - Jun 2000


  • Antinuclear antibodies
  • Autoantibodies
  • Disease activity
  • Interferon beta-Ia
  • Multiple sclerosis
  • Therapeutical response

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Antinuclear antibodies and response to IFNβ-Ia therapy in relapsing-remitting multiple sclerosis'. Together they form a unique fingerprint.

Cite this